ArticleJournal of travel medicine2025
Overseas- and locally acquired sexually transmissible infections in Australia, 2017-23.
Article in Journal of travel medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionInternational travel is a significant contributor to the acquisition of sexually transmissible infections (STIs). Despite the high volume of outbound travel from Australia, peaking at 10.8 million travellers in 2023, limited data exist on the burden of overseas-acquired STIs. This study aims to investigate the burden and trends of overseas- and locally acquired STIs in Australia.
methodsWe analysed STI cases notified to Australia's National Notifiable Diseases Surveillance System (NNDSS) from January 2017 to December 2023. A comparative analysis was conducted by place of acquisition (i.e. overseas versus local), with the geographical origins of overseas-acquired cases mapped using ArcMap and temporal trends assessed across pre-COVID-19, pandemic and post-pandemic periods.
resultsA total of 967 193 records were obtained from NNDSS, of which 188 788 STI cases (11 782 overseas- and 177 006 locally acquired) were included in the analysis. Males were the most affected group (63% of overseas- and 60% of locally acquired), and young adults aged 20-24 years represented a quarter of cases (24.6% of overseas- and 25.9% of locally acquired). The incidence of overseas-acquired STI cases rose nearly threefold, from 12.8 per 100 000 travellers in 2017 to 35.0 per 100 00 travellers in 2019, and then declined during the COVID-19 pandemic due to Australia's travel restrictions to 16.4 per 100 000 travellers in 2020. A surge was observed in 2021, with 46.5 per 100 000 travellers. The most common regions of acquisition were Southeast Asia (n = 2390, 44.6%), North and South America (n = 663, 12.4%) and Northwest Europe (n = 580, 10.8%).
conclusionsThis study highlights the patterns of overseas- and locally acquired STIs in Australia, with chlamydia remaining the most prevalent (but declining since 2021), while gonorrhoea has been increasing, among overseas-acquired cases. Variations in the region of acquisition and demographic factors highlight the critical need for tailored safer-sex advice during pre-travel consultations, particularly for males and young adults travelling to high-prevalence destinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.